IRIS
RAVAGLIA, SABRINA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.298
EU - Europa 1.139
AS - Asia 583
SA - Sud America 3
OC - Oceania 2
AF - Africa 1
Totale 3.026
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.295
CN - Cina 573
IE - Irlanda 371
IT - Italia 201
UA - Ucraina 169
FI - Finlandia 149
DE - Germania 120
GB - Regno Unito 51
SE - Svezia 28
FR - Francia 19
BE - Belgio 13
IN - India 8
CA - Canada 3
CH - Svizzera 3
NL - Olanda 3
BR - Brasile 2
ES - Italia 2
GR - Grecia 2
LU - Lussemburgo 2
RU - Federazione Russa 2
AT - Austria 1
AU - Australia 1
CL - Cile 1
DK - Danimarca 1
KR - Corea 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
RO - Romania 1
SG - Singapore 1
Totale 3.026
Salva come PNG Salva come JPEG
Città #
Chandler 376
Dublin 368
Jacksonville 206
Nanjing 163
Ashburn 97
Beijing 72
Nanchang 60
Helsinki 57
Milan 53
Ann Arbor 52
Jiaxing 52
Lawrence 50
Princeton 50
Medford 49
Hebei 48
Changsha 46
Shenyang 41
Wilmington 41
Pavia 37
Hangzhou 30
New York 30
Boardman 25
Tianjin 20
Trieste 14
Verona 14
Brussels 13
Shanghai 13
Bergamo 12
Woodbridge 10
Los Angeles 7
Seattle 7
Turin 7
Kunming 6
Lodi 6
Norwalk 6
Pune 6
Fairfield 5
Modena 5
Travaco Siccomario 5
Como 4
Dresden 4
Hanover 4
Rome 4
Washington 4
Auburn Hills 3
Cork 3
Naples 3
Saluzzo 3
San Francisco 3
Toronto 3
Athens 2
Bologna 2
Brembate di Sopra 2
Catania 2
Changchun 2
Des Moines 2
Esch-sur-Alzette 2
Falkenstein 2
Udine 2
Vercelli 2
Zhengzhou 2
Zurich 2
Alexandria 1
Amsterdam 1
Auckland 1
Buccinasco 1
Casalpusterlengo 1
Edinburgh 1
Fes 1
Fremont 1
Fuzhou 1
Guangzhou 1
Houston 1
Jinan 1
Krasnoyarsk 1
Lanzhou 1
Leidschendam 1
London 1
Macerata 1
Madrid 1
Marmirolo 1
Messina 1
Monfalcone 1
Munich 1
Ningbo 1
Orange 1
Redwood City 1
San Genesio ed Uniti 1
Shijiazhuang 1
Skopje 1
Sydney 1
Taizhou 1
Torino 1
Vejle 1
Vicchio 1
Vienna 1
Totale 2.255
Salva come PNG Salva come JPEG
Nome #
Mapping the human genetic architecture of COVID-19 124
Enzyme replacement therapy (ERT) in adult-onset type II glycogenosis (GSDII) 82
A Chaperone Enhances Blood α-Glucosidase Activity in Pompe Disease Patients Treated With Enzyme Replacement Therapy. 80
A first update on mapping the human genetic architecture of COVID-19 79
Cognitive impairment and central motor conduction time in chronic alcoholics. 78
Severe recurrent myelitis in patients with hepatitis C virus infection 68
Dietary treatment in adult-onset type II glycogenosis. 67
The angiotensin-converting enzyme insertion/deletion polymorphysm modifies the clinical outcome in patients with Pompe disease. 67
Pathogenetic role of myelitis for syringomyelia. 64
Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. 64
Clinical MRI dissociation in myelopathy: a clue to sarcoidosis? 63
Emicrania emiplegica familiare: dalla genetica alla clinica. 62
Triggering migraine attacks:the role of nitroderivatives. 62
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 61
Recombinant alpha-glucosidase in adult-onset type II glycogenosis: The experience with the first Italian patient, from expanded access programmes to marketing authorization 61
Immune-mediated neuropathies in myeloma patients treated with bortezomib. 61
Efficacy of propafenone in paramyotonia congenita 60
Presyrinx in children with Chiari malformations 60
Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encphalomyelitis. 60
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant. 60
Combined central and peripheral demyelination: comparison of adult and pediatric series 59
Aspetti clinici e patogenetici della comorbidita’ emicranica. 59
Changes in nutritional status and body composition during enzyme replacementtherapy in adult-onset type II glycogenosis. 59
Retinal migraine as unusual feature of cerebral autosomal dominantarteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL) 58
Severe recurrent myelitis in patients with hepatitis C virus infection patients 57
Early-onset ptosis in type II glycogenosis 57
Outcome after Two Years of Enzyme Replacement Therapy (ERT) in 29 Patients with Late-Onset Type II Glycogenosis (GSDII) 56
Recombinant alglucosidase alpha (rhGAA) in adult-onset type II glycogenosis (GSDII): A follow-up study before and after treatment 52
Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease. 52
NMO-IgG-negative relapsing myelitis 51
Strabismo parossistico: Meccanismi corticali e meccanismi periferici nella fisiopatologia di due casi con analoga fenomenologia critica 51
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patientswith Alzheimer's disease and vascular dementia. 48
Post-infectious inflammatory disordes:sub-groups based on prospective follow-up. 46
Enzyme replacement therapy in severe adult-onset glycogen storage disease type II 46
Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. 45
LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population 45
Enzyme replacement therapy in late-onset type II glycogenosis. 44
Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset Type II Glycogenosis? 44
Erectile dysfunction as a sentinel symptom ofcardiovascular autonomic neuropathy in heavy drinkers 42
The diagnosis of migraine: clinical and instrumental aspects 41
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 41
RECOMBINANT ALGLUCOSIDASE ALFA IN ADULT-ONSET GLYCOGENOSIS TYPE II: A FOLLOW-UP STUDY BEFORE AND AFTER TREATMENT 40
Genotype-phenotype correlation in Pompe disease, a step forward. 40
Ocular neuromyotonia with both tonic and paroxysmal components due to vascular compression 40
Severe steroid-resistant post-infectious encephalomyelitis: General features and effects of IVIg 39
Enzyme replacement therapy in adult-onset type II glycogenosis 38
Post-infectious and postvaccinal acute disseminated encephalomyelitis occurring in the same patients 38
Diagnosis and therapy of acute disseminated encephalomyelitis and its variants 35
null 34
Erratum: Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (Journal of Neurology (2014) 261 (438-440) DOI: 10.1007/s00415-013-7217-3) 34
Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up 33
Guillain-Barré syndrome associated with SARS-CoV-2 33
ENZYME REPLACEMENT THERAPY IN LATE-ONSET PHENOTYPES OF GLYCOGENOSIS TYPE 2: RESULTS OF AN ITALIAN MULTICENTER STUDY 30
COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course 30
Adult-onset type II glycogenosis (GSDII): Clinical spectrum and enzyme replacement therapy (ERT) 29
Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2 29
Trunk muscle involvement in late-onset Pompe disease: Study of thirty patients 27
Enzyme replacement therapy with Alglucosidase alfa in juvenile-adult glycogenosis type 2 patients 24
HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review 23
Enzyme replacement therapy in adult-onset glycogenosis II: Is quantitative muscle MRI helpful? 21
Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? 20
Distribution of Exonic Variants in Glycogen Synthesis and Catabolism Genes in Late Onset Pompe Disease (LOPD) 15
Totale 3.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.383
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.383
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 1 2 4
2019/2020685 185 276 1 33 2 35 4 35 3 49 61 1
2020/2021284 39 29 6 33 3 39 2 44 6 40 36 7
2021/2022221 5 3 4 3 0 4 3 11 11 2 36 139
2022/20231.202 84 90 12 174 97 123 2 61 438 13 96 12
2023/2024326 49 73 11 18 28 102 5 26 5 9 0 0
Totale 3.088